Express News | Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
ReutersApr 25 16:01 ET
We're Interested To See How Arcturus Therapeutics Holdings (NASDAQ:ARCT) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring
Simply Wall StApr 17 06:25 ET
As More Rare Disease Therapies Launch, Their Prices Are Rising
Seeking AlphaApr 16 12:22 ET
Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares
Yahoo FinanceMar 28 01:34 ET
Arcturus Therapeutics(ARCT.US) Officer Sells US$610.57K in Common Stock
$Arcturus Therapeutics(ARCT.US)$ Officer Chivukula Pad sold 17,435 shares of Common Stock on Mar 25, 2024 at an average price of $35.02 for a total value of $610.57K.Source: Announcement What is state
moomoo NewsMar 27 16:58 ET
Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing
Pad Chivukula, Chief Scientific Officer & COO, on March 25, 2024, sold 17,435 shares in Arcturus Therapeutics Holdings (ARCT) for $610,574. Following the Form 4 filing with the SEC, Chivukula has cont
MT NewswiresMar 27 16:22 ET
Optimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in Japan
TipRanksMar 26 07:15 ET
Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...
Yahoo FinanceMar 22 01:26 ET
Arcturus Therapeutics(ARCT.US) Officer Sells US$299.84K in Common Stocks
$Arcturus Therapeutics(ARCT.US)$ Officer Chivukula Pad sold 8,565 shares of Common Stocks on Mar 19, 2024 at an average price of $35.0075 for a total value of $299.84K.Source: Announcement What is sta
moomoo NewsMar 21 18:11 ET
Arcturus Therapeutics' Kostaive Vaccine Succeeds in Phase III
TipRanksMar 19 06:12 ET
Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Yahoo FinanceMar 17 09:50 ET
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
In the preceding three months, 4 analysts have released ratings for Arcturus Therapeutics (NASDAQ:ARCT), presenting a wide array of perspectives from bullish to bearish.The table below summarizes thei
BenzingaMar 11 08:01 ET
Express News | Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Raises Price Target to $87
Moomoo 24/7Mar 11 07:51 ET
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)
TipRanksMar 11 00:40 ET
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
Yahoo FinanceMar 9 13:09 ET
Analysts Have Made A Financial Statement On Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Yearly Report
Last week, you might have seen that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its full-year result to the market. The early response was not positive, with shares down 7.2% to US$36.8
Simply Wall StMar 9 07:33 ET
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating
Arcturus Therapeutics Holdings (ARCT) has an average outperform rating and a price target range of $18 to $140, according to analysts polled by Capital IQ. Price: 38.70, Change: +1.51, Percent Change:
MT NewswiresMar 8 09:53 ET
Express News | HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $60 Price Target
Moomoo 24/7Mar 8 09:42 ET
Arcturus Therapeutics Is Maintained at Overweight by Wells Fargo
Arcturus Therapeutics Is Maintained at Overweight by Wells Fargo
Dow JonesMar 8 08:00 ET
Arcturus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/08/2024 62.24% Wells Fargo $45 → $58 Maintains Overweight 02/08/2024 34.27% Citigroup $40 → $48 Maintai
BenzingaMar 8 07:48 ET
No Data
No Data